Zejing pharmaceutical: Approval Notification for Clinical Trial of Injection ZG005 in Combination with Platinum-based Chemotherapy

Zejing Pharmaceutical announced that the company has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration, and the clinical trial of injection ZG005 in combination with platinum-based chemotherapy for advanced nasopharyngeal carcinoma and esophageal squamous cell carcinoma has been approved. This drug is an innovative tumor immunotherapy biological product that is expected to be used in the treatment of various solid tumors. Due to the long research and development cycle of drugs and the multiple approval processes, there is a risk of not being able to obtain approval for marketing, which will not have a significant impact on the company's recent performance.